2022
DOI: 10.1128/spectrum.01158-22
|View full text |Cite
|
Sign up to set email alerts
|

A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints

Abstract: Clinicians often base antimicrobial therapeutic decisions on laboratory determinations of pathogen susceptibility to an antibiotic based on MIC breakpoints. MIC breakpoints evolve over time based on new information; between 2010 and 2012 the CLSI lowered carbapenem breakpoints for Enterobacterales and Pseudomonas aeruginosa , and these were subsequently adopted by the US Food and Drug Administration.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 26 publications
0
2
0
Order By: Relevance
“…This was a retrospective cohort study of data from women with outpatient UTI (positive urine culture and antimicrobial treatment within one day of culture) collected from nine outpatient facilities included in the BD Insights Research Database (Becton, Dickinson and Company, Franklin Lakes, New Jersey, US). This database has been described previously [ 7 ] and provides data from across all US census regions. Urine cultures were collected between January 1, 2015 and December 31, 2019.…”
Section: Methodsmentioning
confidence: 99%
“…This was a retrospective cohort study of data from women with outpatient UTI (positive urine culture and antimicrobial treatment within one day of culture) collected from nine outpatient facilities included in the BD Insights Research Database (Becton, Dickinson and Company, Franklin Lakes, New Jersey, US). This database has been described previously [ 7 ] and provides data from across all US census regions. Urine cultures were collected between January 1, 2015 and December 31, 2019.…”
Section: Methodsmentioning
confidence: 99%
“…For Gram-negative infections with severely antibiotic-resistant pathogens, carbapenems have become the cornerstone of treatment. Meropenem is the most commonly used agent, and doripenem is a newer carbapenem with efficacy against Pseudomonas aeruginosa [ 109 ]. Carbapenems should be used as monotherapy since there is no evidence for increased efficacy when combined with aminoglycosides [ 110 ].…”
Section: Antimicrobial Therapymentioning
confidence: 99%